Compare PHM & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PHM | WST |
|---|---|---|
| Founded | 1950 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.7B | 17.9B |
| IPO Year | 1994 | 2004 |
| Metric | PHM | WST |
|---|---|---|
| Price | $117.57 | $251.02 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 7 |
| Target Price | $137.67 | ★ $319.43 |
| AVG Volume (30 Days) | ★ 1.5M | 781.8K |
| Earning Date | 04-23-2026 | 04-23-2026 |
| Dividend Yield | ★ 0.91% | 0.36% |
| EPS Growth | N/A | ★ 1.49 |
| EPS | ★ 11.12 | 6.79 |
| Revenue | N/A | ★ $2,886,900,000.00 |
| Revenue This Year | N/A | $6.76 |
| Revenue Next Year | $4.64 | $6.15 |
| P/E Ratio | ★ $10.22 | $36.09 |
| Revenue Growth | N/A | ★ 1.95 |
| 52 Week Low | $88.07 | $187.43 |
| 52 Week High | $144.50 | $322.34 |
| Indicator | PHM | WST |
|---|---|---|
| Relative Strength Index (RSI) | 41.14 | 58.22 |
| Support Level | $114.04 | $239.86 |
| Resistance Level | $122.27 | $261.98 |
| Average True Range (ATR) | 3.28 | 6.69 |
| MACD | -0.16 | 1.42 |
| Stochastic Oscillator | 45.87 | 98.92 |
PulteGroup Inc is a homebuilder in the United States. The company mainly builds single-family detached homes and offers products to entry-level, move-up, and active-adult buyers. It also offers homebuyers mortgage financing, title, and insurance agency services through its financial services segment.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.